IL164861A0 - Trans-epicutaneous administration form for treating restless leg syndrome - Google Patents

Trans-epicutaneous administration form for treating restless leg syndrome

Info

Publication number
IL164861A0
IL164861A0 IL16486103A IL16486103A IL164861A0 IL 164861 A0 IL164861 A0 IL 164861A0 IL 16486103 A IL16486103 A IL 16486103A IL 16486103 A IL16486103 A IL 16486103A IL 164861 A0 IL164861 A0 IL 164861A0
Authority
IL
Israel
Prior art keywords
restless leg
leg syndrome
trans
administration form
rotigotin
Prior art date
Application number
IL16486103A
Other languages
English (en)
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29285132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL164861(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of IL164861A0 publication Critical patent/IL164861A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16486103A 2002-05-06 2003-05-05 Trans-epicutaneous administration form for treating restless leg syndrome IL164861A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10220230A DE10220230A1 (de) 2002-05-06 2002-05-06 Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
PCT/EP2003/004685 WO2003092677A1 (de) 2002-05-06 2003-05-05 Transepikutane darreichungsform zur behandlung des restless leg syndroms

Publications (1)

Publication Number Publication Date
IL164861A0 true IL164861A0 (en) 2005-12-18

Family

ID=29285132

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16486103A IL164861A0 (en) 2002-05-06 2003-05-05 Trans-epicutaneous administration form for treating restless leg syndrome
IL164861A IL164861A (en) 2002-05-06 2004-10-27 Use of rotigotine for the production of a medicament for treating restless leg syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL164861A IL164861A (en) 2002-05-06 2004-10-27 Use of rotigotine for the production of a medicament for treating restless leg syndrome

Country Status (23)

Country Link
EP (1) EP1501499B1 (enExample)
JP (2) JP5253707B2 (enExample)
KR (1) KR20040104697A (enExample)
CN (1) CN100396281C (enExample)
AT (1) ATE387912T1 (enExample)
AU (1) AU2003233233B2 (enExample)
BR (1) BR0309837A (enExample)
CA (2) CA2483120C (enExample)
CY (1) CY1107452T1 (enExample)
DE (2) DE10220230A1 (enExample)
DK (1) DK1501499T3 (enExample)
ES (1) ES2301795T3 (enExample)
IL (2) IL164861A0 (enExample)
MX (1) MXPA04010687A (enExample)
NO (1) NO333619B1 (enExample)
NZ (1) NZ536533A (enExample)
PL (1) PL218549B1 (enExample)
PT (1) PT1501499E (enExample)
RU (1) RU2301063C9 (enExample)
SI (1) SI1501499T1 (enExample)
UA (1) UA81625C2 (enExample)
WO (1) WO2003092677A1 (enExample)
ZA (1) ZA200408862B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10359528A1 (de) * 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
ES2466647T3 (es) * 2006-05-08 2014-06-10 Teikoku Seiyaku Co., Ltd. Preparación absorbible por vía transdérmica que comprende un agente contra la demencia
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MY165575A (en) 2007-11-28 2018-04-05 Ucb Pharma Gmbh Polymorphic form of rotigotine
US20110028880A1 (en) 2008-02-27 2011-02-03 Hisamitsu Pharmaceutical Co., Inc. Patch
JP5546013B2 (ja) 2008-02-27 2014-07-09 久光製薬株式会社 貼付剤及び包装体
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
CN102665699A (zh) 2009-12-22 2012-09-12 优时比制药有限公司 用于使非结晶形式的罗替戈汀的固体分散体稳定化的聚乙烯吡咯烷酮
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
BR112012029944A2 (pt) 2010-06-25 2019-09-24 Ucb Pharma Gmbh processo para preparação de derivados de aminotetralinas substituídas com nitrogênio
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
EP2870963A4 (en) * 2012-07-06 2016-03-09 Sk Chemicals Co Ltd PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
MX2016011152A (es) 2014-02-27 2016-12-09 Medrx Co Ltd Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa.
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
KR102401412B1 (ko) 2019-06-14 2022-05-23 히사미쓰 세이야꾸 가부시키가이샤 로티고틴 함유 첩부제
FI3854388T3 (fi) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US5482988A (en) * 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
DK1256339T3 (da) * 2001-05-08 2004-02-09 Sanol Arznei Schwarz Gmbh Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom

Also Published As

Publication number Publication date
PL373276A1 (en) 2005-08-22
NO333619B1 (no) 2013-07-22
CA2483120A1 (en) 2003-11-13
MXPA04010687A (es) 2005-06-08
RU2004131866A (ru) 2005-06-10
RU2301063C9 (ru) 2007-11-27
RU2301063C2 (ru) 2007-06-20
PL218549B1 (pl) 2014-12-31
CA2483120C (en) 2013-07-16
KR20040104697A (ko) 2004-12-10
ES2301795T3 (es) 2008-07-01
SI1501499T1 (sl) 2008-06-30
AU2003233233A1 (en) 2003-11-17
BR0309837A (pt) 2005-03-01
CA2787384A1 (en) 2003-11-13
JP5253707B2 (ja) 2013-07-31
ZA200408862B (en) 2005-09-28
NZ536533A (en) 2010-02-26
UA81625C2 (ru) 2008-01-25
HK1072541A1 (zh) 2005-09-02
DK1501499T3 (da) 2008-06-23
CY1107452T1 (el) 2012-12-19
AU2003233233B2 (en) 2008-03-06
JP2005528413A (ja) 2005-09-22
DE50309318D1 (de) 2008-04-17
JP2010159302A (ja) 2010-07-22
CN1665497A (zh) 2005-09-07
NO20045240L (no) 2004-11-30
DE10220230A1 (de) 2003-11-27
EP1501499A1 (de) 2005-02-02
EP1501499B1 (de) 2008-03-05
IL164861A (en) 2011-06-30
WO2003092677A1 (de) 2003-11-13
ATE387912T1 (de) 2008-03-15
PT1501499E (pt) 2008-05-20
CN100396281C (zh) 2008-06-25

Similar Documents

Publication Publication Date Title
IL164861A0 (en) Trans-epicutaneous administration form for treating restless leg syndrome
RU2003133217A (ru) Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме
RU2003128642A (ru) Улучшенная чрескожная терапевтическая система для лечения болезни паркинсона
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
CA2339221A1 (en) Extracts of feverfew (tanacetum parthenium) against inflammatory disorders
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
PL309721A1 (en) Pharmaceutical composition containing fluoxetin hydrochloride
DK0828500T3 (da) Anvendelse af flavanyllignaner til fremstilling af lægemidler med proliferativ aktivitet i uturus, ovarie og bryst
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
EP1248629A4 (en) TREATMENT AND PREVENTION OF BACTERIAL PULMONARY INFECTION OR SYMPTOMATIC PULMONARY EXPOSURE TO ENDOTOXINS BY INHALATION OF ANTI-ENDOTOXIN DRUGS
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
BRPI0407178A (pt) Composição farmacêutica osteogênica
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
GB2446341A (en) Method and system for transdermal drug delivery
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
TW200719903A (en) Compositions for the treatment of neoplasms
SE0102887D0 (sv) New formulation
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
TW200618807A (en) Prevention and therapeutical agent for hepatitis C virus infection
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence